RecruitingNCT07547098

Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome


Sponsor

First Affiliated Hospital of Fujian Medical University

Enrollment

8,000 participants

Start Date

Mar 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and/or metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive monthly data updates to support risk stratification, real-world evidence generation, and CKM management pathway optimization.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria6

  • Age 18 years or older.
  • Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage.
  • Cardiovascular disease, kidney disease, metabolic disease, or key examination/laboratory information supporting CKM phenotyping.
  • Willingness to participate and provision of written informed consent.
  • Ability to complete baseline assessment and follow-up.
  • Full civil capacity and ability to understand study information.

Exclusion Criteria6

  • Refusal to provide written informed consent.
  • Severe psychiatric disease or cognitive impairment precluding participation.
  • End-stage disease with expected survival less than 1 year.
  • Long-term absence more than 6 months preventing reliable follow-up.
  • Participation in another clinical study that may interfere with endpoint adjudication.
  • Missing key fields preventing linkage of examinations, imaging, and outcomes.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07547098


Related Trials